Browse by Phase
Phase 2 Clinical Trials
Phase 2 trials study whether a drug works in people with a specific disease or condition. These studies enroll 100–300 participants and also continue to evaluate safety.
Total Trials
1,078
Recruiting Now
1,078
Top Conditions in Phase 2
Frequently Asked Questions — Phase 2 Trials
What does a Phase 2 clinical trial evaluate?
Phase 2 trials assess whether a drug or treatment works in people with a specific disease or condition. Enrolling 100–300 participants, these studies collect preliminary efficacy data while continuing to monitor safety and identify the optimal dosing regimen. A successful Phase 2 outcome is required to advance to large-scale Phase 3 testing.
How long do Phase 2 trials typically take?
Phase 2 clinical trials typically run for 1–4 years, depending on the condition, endpoint complexity, and enrollment rate. Rare disease trials or those with long-term outcome measures may run longer. Many sponsors run Phase 2 studies at multiple sites simultaneously to accelerate recruitment.
Who can participate in a Phase 2 clinical trial?
Eligibility for Phase 2 trials is defined by specific inclusion and exclusion criteria. Participants are typically patients diagnosed with the condition under study and may or may not have received prior treatment. Age, disease stage, comorbidities, and laboratory values are common eligibility factors. Review each trial's criteria on ClinicalTrials.gov for specific requirements.
Active Phase 2 Studies
NCT05805605 Phase 2
Recruiting
Allo HSCT Using RIC and PTCy for Hematological Diseases
Condition
Acute Myelogenous Leukemia
Enrollment
56 pts
Location
United States
Sponsor
Masonic Cancer Center, Univers
NCT07464756 Phase 2
Recruiting
SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvan...
Condition
Gastric Adenocarcinoma
Enrollment
80 pts
Location
China
Sponsor
The First Affiliated Hospital
NCT06965231 Phase 2
Recruiting
Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial
Condition
Melanoma of Skin
Enrollment
58 pts
Location
China
Sponsor
Fudan University
NCT06806202 Phase 2
Recruiting
Warm Versus Conventional 2% Lignocaine for IANB Efficacy
Condition
Success of Inferior Alveolar Nerve Block
Enrollment
200 pts
Location
Pakistan
Sponsor
Armed Forces Institute of Dent
NCT06271057 Phase 2
Recruiting
Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients Wit...
Condition
Diffuse Large B-cell Lymphoma Refractory
Enrollment
65 pts
Location
France
Sponsor
The Lymphoma Academic Research
NCT05535166 Phase 2
Recruiting
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With...
Condition
Medulloblastoma
Enrollment
130 pts
Location
United States
Sponsor
St. Jude Children's Research H
NCT06136546 Phase 2
Recruiting
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Vi...
Condition
Depressive Disorder, Major
Enrollment
100 pts
Location
United States
Sponsor
Massachusetts General Hospital
NCT06022003 Phase 2
Recruiting
Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine ...
Condition
AML, Adult
Enrollment
33 pts
Location
France
Sponsor
French Innovative Leukemia Org
NCT07069569 Phase 2
Recruiting
A Multicenter Study of AHB-137 Injection Combined With Other Hepatitis B Drugs
Condition
Chronic Hepatitis B
Enrollment
200 pts
Location
China
Sponsor
Ausper Biopharma Co., Ltd.
NCT06906341 Phase 2
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With G...
Condition
Ovarian Cancer
Enrollment
270 pts
Location
United States, Belgium, France
Sponsor
Corcept Therapeutics
NCT00412594 Phase 2
Recruiting
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
Condition
Hairy Cell Leukemia
Enrollment
150 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT05969275 Phase 2
Recruiting
Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock
Condition
Septic Shock
Enrollment
296 pts
Location
Canada
Sponsor
Ottawa Hospital Research Insti
NCT06751901 Phase 2
Recruiting
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced ...
Condition
Advanced NSCLC
Enrollment
10 pts
Location
China
Sponsor
The First Affiliated Hospital
NCT01624805 Phase 2
Recruiting
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and...
Condition
Aplastic Anemia
Enrollment
140 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT06182839 Phase 2
Recruiting
Canagliflozin in Advanced Renal Disease With MRI Endpoints
Condition
ESRD, CKD Stage 4, CKD Stage 5
Enrollment
92 pts
Location
Canada
Sponsor
McGill University Health Centr
NCT06640283 Phase 2
Recruiting
Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up...
Condition
HPV-Related Carcinoma
Enrollment
150 pts
Location
Brazil
Sponsor
Instituto do Cancer do Estado
NCT04583254 Phase 2
Recruiting
Hypofractionated External-beam RadiOtherapy for Intact Cervical Cancer (HEROICC-...
Condition
Cervical Cancer
Enrollment
48 pts
Location
Canada
Sponsor
London Health Sciences Centre
NCT04414046 Phase 2
Recruiting
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Im...
Condition
Primary Immune Deficiency Disorders
Enrollment
17 pts
Location
United States
Sponsor
Johns Hopkins All Children's H
NCT07213570 Phase 2
Recruiting
STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorect...
Condition
Colorectal Cancer Metastatic
Enrollment
60 pts
Location
Italy
Sponsor
National Cancer Institute, Nap
NCT04812366 Phase 2
Recruiting
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Pr...
Condition
Prostate Cancer
Enrollment
315 pts
Location
United States, Canada
Sponsor
University of British Columbia
NCT06638931 Phase 2
Recruiting
Agnostic Therapy in Rare Solid Tumors
Condition
Urachal Cancer
Enrollment
28 pts
Location
Brazil
Sponsor
Instituto do Cancer do Estado
NCT05604131 Phase 2
Recruiting
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Condition
Acute Myocardial Infarction Type 1
Enrollment
89 pts
Location
United States
Sponsor
Rohan Dharmakumar
NCT07229742 Phase 2
Recruiting
A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in th...
Condition
Active Lupus Nephritis
Enrollment
51 pts
Location
China
Sponsor
Guangdong Hengrui Pharmaceutic
NCT07610369 Phase 2
Recruiting
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
Condition
Depression
Enrollment
40 pts
Location
United States
Sponsor
Yale University
NCT06848569 Phase 2
Recruiting
Sintilimab Plus AVD in Pediatric Low/Moderate Risk Hodgkin Lymphoma: A Phase II ...
Condition
Classical Hodgkin Lymphoma
Enrollment
73 pts
Location
China
Sponsor
Sun Yat-sen University
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology